Vitamin B12 largely reversed growth and developmental problems in worms carrying a mutation linked to Verheij syndrome, according to a report about a study published in Nature Communications. The researchers also found evidence of similar metabolic changes in human cells and patient blood samples. Whether vitamin B12 can improve symptoms in people with the rare disorder remains unknown.
The work connects a problem in RNA splicing—the process cells use to prepare genetic instructions for making proteins—with changes in metabolism. When splicing goes wrong, it can affect essential cellular functions. Mutations in genes involved in this process can cause disorders including Verheij syndrome, which is associated with developmental delays and impaired growth.
The researchers investigated a mutation in a splicing-related gene that is also associated with Verheij syndrome in people. Their experiments used C. elegans, a tiny roundworm commonly studied in biology. The team had been looking for genes that influence lifespan when it examined the mutation. Worms carrying it grew slowly and stayed smaller than normal, showing some features relevant to the human condition, though a worm model cannot establish what will happen in patients.
Genetic screens and metabolic analyses pointed to changes in pathways that depend on vitamin B12 and are important for growth and normal cellular activity. When the researchers supplied additional vitamin B12 to the worms, the affected metabolic processes returned to normal and the developmental abnormalities were largely corrected. Jonathan Kölschbach, identified in the report as the study’s first author, said the team was surprised that a change in RNA processing had such a targeted effect on B12-dependent metabolism.
To explore whether the finding might also matter in people, the researchers examined publicly available datasets from human cells and worked with Hormos Dafsari, a neuropediatrician at University Hospital Cologne, to collect blood samples from people diagnosed with Verheij syndrome. These investigations found evidence of similar metabolic changes in humans. They did not establish that vitamin B12 supplementation would correct those changes or improve patients’ symptoms.
That distinction is central to the result. The worm experiments suggest that changing B12 availability can counter some effects of this mutation in a model organism. The human observations make the metabolic link relevant to investigate further, but they are not evidence that the vitamin is an effective treatment for people with Verheij syndrome. Additional studies would be needed to test whether the model’s benefits translate to patients.
The findings may also point researchers toward a broader question: whether metabolic disruptions contribute to other diseases caused by faulty RNA splicing. The report presents that as a possibility, not an established result. Adam Antebi, director at the Max Planck Institute for Biology of Ageing and identified as the study’s lead author, described the work as an example of how basic research in model organisms can generate ideas with potential long-term medical relevance.
The report was based on materials provided by the Max Planck Institute for Biology of Ageing.